PK and PD parameters by mavorixafor daily dose
| Treatment . | Tmax, median (range), h . | Cmax, median (range), ng/mL . | AUC0-24, median (range), h × ng/mL . | TATANC >500 cells/μL, median (range), h . | TATALC >1000 cells/μL, median (range), h . |
|---|---|---|---|---|---|
| 50 mg (n = 2) | 1.25 (0.50-2.00) | 117 (85-148) | 262 (173-352) | 0.00 (0.00-0.00) | 6.87 (1.71-12.02) |
| 100 mg (n = 4) | 1.25 (1.00-2.00) | 514 (337-890) | 1090 (497-3 480) | 1.93 (0.00-7.27) | 14.29 (1.47-19.41) |
| 150 mg (n = 2) | 1.75 (1.50-2.00) | 633 (271-994) | 1680 (606-2 760) | 0.00 (0.00-0.00) | 9.01 (2.73-15.28) |
| 200 mg (n = 3) | 1.50 (1.00-2.00) | 956 (614-1290) | 3830 (1 980-3 870) | 2.28 (0.00-7.51) | 16.32 (11.16-17.01) |
| 300 mg* | 2.00 (0.50-3.00) | 2430 (295-4140) | 9500 (1 370-16 500) | 8.60 (0.00-24.00) | 18.13 (9.64-24.00) |
| 400 mg (n = 3) | 2.00 (1.50-2.00) | 2260 (1340-3080) | 8060 (7 510-9 880) | 13.85 (1.73-24.00) | 15.79 (4.83-16.05) |
| Treatment . | Tmax, median (range), h . | Cmax, median (range), ng/mL . | AUC0-24, median (range), h × ng/mL . | TATANC >500 cells/μL, median (range), h . | TATALC >1000 cells/μL, median (range), h . |
|---|---|---|---|---|---|
| 50 mg (n = 2) | 1.25 (0.50-2.00) | 117 (85-148) | 262 (173-352) | 0.00 (0.00-0.00) | 6.87 (1.71-12.02) |
| 100 mg (n = 4) | 1.25 (1.00-2.00) | 514 (337-890) | 1090 (497-3 480) | 1.93 (0.00-7.27) | 14.29 (1.47-19.41) |
| 150 mg (n = 2) | 1.75 (1.50-2.00) | 633 (271-994) | 1680 (606-2 760) | 0.00 (0.00-0.00) | 9.01 (2.73-15.28) |
| 200 mg (n = 3) | 1.50 (1.00-2.00) | 956 (614-1290) | 3830 (1 980-3 870) | 2.28 (0.00-7.51) | 16.32 (11.16-17.01) |
| 300 mg* | 2.00 (0.50-3.00) | 2430 (295-4140) | 9500 (1 370-16 500) | 8.60 (0.00-24.00) | 18.13 (9.64-24.00) |
| 400 mg (n = 3) | 2.00 (1.50-2.00) | 2260 (1340-3080) | 8060 (7 510-9 880) | 13.85 (1.73-24.00) | 15.79 (4.83-16.05) |
n = 7 for Tmax, Cmax and AUC0-24h; n = 6 for TATANC and TATALC because of the exclusion of 1 subject with chronic infection that could bias the PD results.